LKFT — Lakefront Biotherapeutics NV Share News
0.000.00%
Last trade - 00:00- €1.69bn
- -€1.28bn
- €1.11bn
Galapagos tops BEL20 on encouraging trial data for cancer treatment
Brief: Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024
Brief: Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications
Galapagos jumps on collaboration with Blood Centers of America
Brief: Galapagos Says Total Operating Loss From Continuing Operations For Three Months Ended 31 March 2024 Was EUR 33.1 Million
Brief: Galapagos Q1 Cash & Investments EUR 3,600 Million
Galapagos NV expected to post a loss of 14 cents a share - Earnings Preview
Europe Research Roundup: Alfen, Boliden, Pennon Group
Brief: Galapagos Appoints Andrew Dickinson As Non-Executive Non-Independent Director To Its Board
Galapagos NV reports results for the quarter ended in December - Earnings Summary
Galapagos NV expected to post a loss of €3.93 a share - Earnings Preview
Brief: Galapagos Enters Into Strategic Collaboration With Thermo Fisher Scientific To Further Expand Its Decentralized CAR-T Manufacturing Network
Brief: Galapagos To Transfer Jyseleca Business To Alfasigma
Brief: Galapagos Announces Start Of Papilio-1 Phase 1/2 Multiple Myeloma Study
Europe Research Roundup: Auction Technology Group, Euroapi SA, Land Securities
Europe Research Roundup: Entain, Fresenius Medical Care, Indivior
Brief: Landmark Bio to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Galapagos rises on narrowing losses, guidance confirmation
Galapagos NV reports results for the quarter ended in September - Earnings Summary